Autoimmune Disease Emerges as a Patient-Level Risk Factor for Breast Cancer Lymphedema
Preexisting autoimmune disease was associated with a materially higher risk of breast cancer-related lymphedema after axillary surgery, adding a host factor to a complication long driven by treatment intensity alone. In a retrospective cohort of 20,027 adults treated at a tertiary cancer center, autoimmune disease independently increased the hazard of lymphedema even after adjustment for demographic and treatment variables.
The signal was not subtle. Patients with autoimmune disease developed lymphedema more often than those without it, and the excess risk persisted across both sentinel lymph node biopsy and axillary lymph node dissection cohorts. For a complication that can carry chronic swelling, pain, recurrent infection, and durable functional loss, the finding matters at the bedside where risk counseling and surveillance are set before surgery even begins.
Cohort Size, Follow-up, and Baseline Risk
The study drew from adults who underwent sentinel lymph node biopsy and/or axillary lymph node dissection for breast cancer between 2010 and 2021. Median follow-up reached 61.7 months, with an interquartile range of 38.7 to 94.2 months, giving enough time for lymphedema to emerge well beyond the immediate postoperative period. Most patients were female, median age at axillary surgery was 55 years, and median body mass index was 25.0 kg/m2.
Treatment exposure was substantial. Axillary lymph node dissection was performed in 19% of patients, breast-conserving surgery in 61%, chemotherapy in 52%, radiotherapy in 66%, and endocrine therapy in 77%. Lymphedema developed in 1728 patients, or 8.6% of the cohort, at a median of 17.4 months after surgery. Cumulative incidence rose from 5.6% at 24 months to 8.1% at 48 months and 12% at 144 months.
One line in the dataset stood out immediately: the lymphedema burden after axillary lymph node dissection was far higher than after sentinel node biopsy. Incidence reached 28% with axillary dissection versus 4% with sentinel node biopsy.
Autoimmunity Increased Risk Even After Adjustment
Autoimmune disease was present in 1361 patients, or 6.8% of the cohort. It appeared more often among patients who developed lymphedema than among those who did not. The most common conditions were rheumatoid arthritis, autoimmune thyroiditis, Graves’ disease, and antiphospholipid syndrome.
In univariate analysis, any autoimmune disease was associated with higher lymphedema risk. The association remained in multivariable modeling, where autoimmune disease carried a hazard ratio of 1.52. The confidence interval excluded unity, and the P value was less than .001, supporting an independent relationship rather than a byproduct of surgery type, radiation, chemotherapy, race, or body mass index.
Several individual diagnoses were also linked to elevated risk. Rheumatoid arthritis carried a hazard ratio of 1.54, autoimmune thyroiditis 1.40, Graves’ disease 1.59, multiple sclerosis 1.87, systemic lupus erythematosus 2.46, and systemic sclerosis 2.10. The strongest association appeared with systemic lupus erythematosus, where the point estimate more than doubled the risk.
Why Inflammation May Leave the Lymphatic System Less Resilient
The biology fits the clinical pattern. Lymphedema is not simply postoperative swelling; it is a chronic inflammatory disorder in which lymphatic injury leads to fluid stasis, immune activation, progressive fibrosis, and fibroadipose deposition. Once the balance tips, tissue remodeling can become self-sustaining, with reduced lymphatic transport and recurring inflammatory injury reinforcing one another.
Autoimmune disease can place the lymphatic system under persistent immune pressure before breast cancer treatment ever begins. Chronic cytokine signaling, endothelial injury, and fibrosis may reduce lymphatic reserve, so that surgical disruption or radiation pushes an already strained system into failure. T-helper 2 skewing, macrophage infiltration, and profibrotic signaling offer a plausible bridge between systemic autoimmunity and local lymphatic dysfunction.
That mechanism is especially persuasive in systemic lupus erythematosus and systemic sclerosis, where immune activation and tissue fibrosis are central features. The lymphatic circulation may tolerate a single insult, but repeated inflammatory pressure can erode the capacity to recover from axillary injury.
Risk Extended Across Surgical Approaches and Other Known Predictors
Autoimmune disease did not replace the classic predictors of lymphedema; it joined them. Axillary lymph node dissection remained the strongest treatment-related driver, with a hazard ratio of 4.01. Mastectomy also carried higher risk than breast-conserving surgery. Adjuvant chemotherapy, neoadjuvant chemotherapy, and any radiotherapy were each associated with increased risk. Higher body mass index contributed incrementally, and Black race was also independently associated with lymphedema.
The key clinical point is that autoimmune disease added risk on top of the usual surgical and adjuvant therapy profile. Even among patients who underwent sentinel lymph node biopsy, autoimmune disease still tracked with higher lymphedema incidence, suggesting that immune vulnerability is not dependent on the most extensive axillary operations alone.
What This Means for Surgical Counseling and Surveillance
The study strengthens the argument for treating autoimmune disease as part of preoperative lymphedema risk stratification. Patients with rheumatoid arthritis, lupus, systemic sclerosis, multiple sclerosis, or autoimmune thyroid disease may merit closer attention after axillary surgery, even when the nodal operation is limited. The data also support more explicit counseling before surgery about swelling risk, particularly when additional exposures such as radiation or chemotherapy are planned.
For breast cancer teams, the practical implication is not to avoid necessary cancer treatment, but to recognize that baseline immune biology may shape recovery of the lymphatic system. Earlier symptom review, lower thresholds for referral, and proactive surveillance may be especially important in patients with systemic immune disease.
The study also leaves a clear boundary around interpretation. Autoimmune diagnoses were identified through ICD codes, and lymphedema was also defined through coded records, so the analysis depends on administrative classification rather than direct physiologic measurement. Even so, the size of the cohort, the duration of follow-up, and the persistence of association after multivariable adjustment make the signal difficult to dismiss.
Further work will need to determine whether specific autoimmune phenotypes, treatment exposures for the autoimmune condition itself, or markers of inflammatory burden sharpen prediction beyond diagnosis alone. For now, the message is concrete: in breast cancer survivors, autoimmune disease is not only a comorbidity. It is a measurable risk factor for a chronic and often underappreciated complication.